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Background: Opioids are associated with wide inter-individual variability in the analgesic response and a narrow
therapeutic index. This may be partly explained by the presence of single nucleotide polymorphisms (SNPs) in
genes encoding molecular entities involved in opioid metabolism and receptor activation. This paper describes the
investigation of SNPs in three genes that have a functional impact on the opioid response: OPRM1, which codes for
the μ-opioid receptor; ABCB1 for the ATP-binding cassette B1 transporter enzyme; and the calcium channel
complex subunit CACNA2D2. The genotyping was combined with an analysis of plasma levels of the opioid
peptide β-endorphin in 80 well-defined patients with chronic low back pain scheduled for spinal fusion surgery,
and with differential sensitivity to the opioid analgesic remifentanil. This patient group was compared with 56
healthy controls.
Results: The plasma β-endorphin levels were significantly higher in controls than in pain patients.
A higher incidence of opioid-related side effects and sex differences was found in patients with the minor allele of
the ABCB1 gene. Further, a correlation between increased opioid sensitivity and the major CACNA2D2 allele was
confirmed. A tendency of a relationship between opioid sensitivity and the minor allele of OPRM1 was also found.
Conclusions: Although the sample cohort in this study was limited to 80 patients it appears that it was possible to
observe significant correlations between polymorphism in relevant genes and various items related to pain
sensitivity and opioid response. Of particular interest is the new finding of a correlation between increased opioid
sensitivity and the major CACNA2D2 allele. These observations may open for improved strategies in the clinical
treatment of chronic pain with opioids.
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The treatment of moderate to severe pain is largely
dependent on the use of opioids [1]. Opioids have a nar-
row therapeutic index with wide variations in individual
response [2]. Significant individual differences in sensi-
tivity to these drugs can impair effective pain treatment
and increase side effects. It is assumed that individual
differences in opioid sensitivity may be due in part to
genetic differences in the molecular elements involved in
the pharmacokinetics and pharmacodynamics of opioids.
Thus, genetic variability such as polymorphisms in the
genes coding for opioid-metabolizing enzymes, trans-
porter proteins, and the μ-opioid receptor could partly
explain the observed inter-individual variations in
response to opioids [3-5].
New molecular and genetic techniques have now made
it possible to identify specific genes coding for pain-
relevant proteins, genes that contain mutations that
could explain the variations in pain response [6,7] as
well as the differences in response to pain relieving
drugs. Mutant mice and microarray studies have so far
discovered approximately 200 protein entities thought to
be involved in pain processing, and the genes coding for
these proteins have been systematically investigated as
candidate genes that may be relevant to pain perception
[8]. Variations in these genes, single nucleotide poly-
morphisms (SNPs) or haplotypes (combination of alleles
inherited together), are now being investigated in clinical
populations (for review see [9]).
Since pain is a complex bio-psychosocial phenomenon,
the task of searching for and finding single gene varia-
tions to explain individual differences could be seen as
futile. However, in this study, the focus is on three genes,
all of which encode proteins related to the pain-relieving
effects of opioids, and on the endogenous opioid peptide
β-endorphin. The search for candidate genes containing
SNPs possibly associated with pain and opioid sensitivity
resulted in the choice of the μ-opioid peptide receptor
(OPRM1) gene [10-12], the ATP-binding cassette B1
(ABCB1) gene [13,14] and the calcium channel complex
subunit (CACNA2D2) gene [8]. In the present study, the
occurrence of SNPs in these genes was correlated with
levels of circulating β-endorphin and clinical data from a
well-characterized patient group with chronic low-back
pain and differential sensitivity to the opioid remifen-
tanil. The patients were classified as high responders,
normal responders or non-responders to remifentanil by
an intravenous opioid testing procedure (for details see
Methods).
We chose to analyze an SNP at position 118 (A118G
or 118A>G) of the gene for the OPMR1 receptor, since
this has been shown in earlier studies to alter the re-
sponse to opioids [10]. The 118A>G mutation changes
the base adenine to guanine, with the consequence thatthe amino acid asparagine is changed to aspartic acid at
position 40 of the OPMR1 amino acid sequence. As this
change occurs on the extracellular part of the receptor,
it results in an additional net charge with loss of a puta-
tive glucosylation site in the area of the ligand-receptor
interaction. This can result in differences in opioid sensi-
tivity, clinically manifested as altered analgesic require-
ments [15-17], variations in pain sensitivity [18], or
altered propensity for opioid addiction [10]. The major
allele is AA and, in this study, the minor allele was
defined as the joint AG/GG allele, because of the low
frequency of the homozygous minor allele GG.
The ABCB1 gene is composed of 28 exons ranging in
size from 49 to 209 base pairs, encoding an mRNA of
4.5 kb. The most common polymorphisms found in
ABCB1 are 1236C>T, 2677 G>T/A/C, and 3435C>T.
The transport protein P-glycoprotein, a product of the
ABCB1 gene, plays an important role in the absorption
and distribution of many drugs. P-glycoprotein is an
ATPase-powered enzyme that transports substances,
including opioids, across cell membranes and the
blood–brain barrier [19,20], which regulates central
nervous system exposure to drugs. It has been suggested
that genetic variations in ABCB1 could be a cause of
inter-individual differences in drug response [21]. In this
study, we investigated the C3435T SNP in exon 26 of
ABCB1, where C>T. Thus, the major allele is CC, the
heterozygous minor allele is CT and the homozygous
minor allele is TT.
The CACNA2D2 gene encodes a member of the
alpha-2/delta subunit family, a protein in the voltage-
dependent calcium channel complex [22]. Calcium chan-
nels mediate the influx of calcium ions into the cell
upon membrane polarization and consist of a complex
of alpha-1, alpha-2/delta, beta, and gamma subunits in a
1:1:1:1 ratio [22]. It has been demonstrated that this cal-
cium channel interacts with the G-protein that mediates
the effects of the μ-opioid receptor [23], with potential
effects on pain and opioid requirements [24]. The α2δ
fragment is also the effect site for gabapentin and prega-
balin, drugs used for treating neuropathic pain [25]. The
major allele is GG, the heterozygous allele is AG and the
minor homozygous allele is AA [26].
β-endorphin is an opioid peptide produced primarily
in the anterior lobe of the pituitary gland [27]. Following
release from its precursor protein, pro-opiomelanocortin
(POMC), β-endorphin is circulated via the blood stream
to interact with specific opioid receptors located
throughout the body [28]. The peptide interacts primar-
ily with the μ-opioid peptide (MOP) receptor, although
it can also bind to and activate other opioid receptors,
e.g. the delta receptor [29]. It produces analgesia by inhi-
biting the firing of peripheral somatosensory fibers.
Stress-induced increases in the release of β-endorphin
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whereas administration of exogenous opioids, such as
fentanyl, reduces plasma levels of the peptide [27]. In
experimental animals, exogenous opioids such as mor-
phine have been shown to down-regulate the expression
of POMC and subsequently induce a decrease in the
biosynthesis of β-endorphin [30]. It has been suggested
that decreased β-endorphin concentrations may play a
role in a variety of chronic pain disorders [27].
Thus, in order to move the issue of the genetic aspects
of chronic pain and opioid sensitivity a step forward, we
investigated the influence of SNPs in the μ-receptor
gene OPRM1, the ABCB1 gene for the drug transporter
P-glycoprotein and the calcium channel fragment gene
α2δ CACNAD2, as well as the endogenous ligand for
the μ-opioid receptor β-endorphin. These three candi-
date genes, all associated with pain processing and
opioid analgesia, were analyzed in blood samples col-
lected from 80 patients with chronic low back pain and
56 healthy controls. We also collected plasma samples
for assessment of β-endorphin levels. The patients were
classified as high responders (N=16), normal responders
(N=44) or non-responders (N= 20) to the opioid remi-
fentanil. All the study participants filled out an EORTC
QLQ-30 Quality of Life (QoL) form for pain, function
and symptom scoring.
Results
The genotype frequencies of the minor allele of OPRM1,
ABCB1 and CACNA2D2 are presented in Table 1, and were
in accordance with Hardy-Weinberg equilibrium [31].
β-endorphin levels
β-endorphin plasma levels were determined by radio-
immunoassay (RIA) in patients and healthy controls
(Table 2). The opioid responders had higher levels of
β-endorphin (26.6 ± 3.59 fmol/ml) than the non-
responders (24.7 ± 3.20 fmol/ml; p < 0.05) and the
patients had lower β-endorphin levels (26.2 ± 3.57 fmol/ml)
than the healthy controls (28.2 ± 4.63 fmol/ml; p < 0.01).
OPRM1
The major and minor alleles of OPRM1 were distributed
as presented in Table 1, which shows an apparent higherTable 1 Genotype frequencies
Gene SNP High responder N
N=16
OPRM1 A>G 44% N=7
ABCB1 C>T 32% N=5
CACNA2D2 G>A 0% N=0
Percentage of minor alleles of the OPMR1, ABCB1, and CACNA2D2 genes in high-, n
the GG allele of OPRM1, the minor allele was defined as the combined AG/GG alleleincidence of the minor allele among the high responders
than among the other participants. The genotype
frequency of the minor allele was 7/16 (44%) in high
responders, 8/44 (22%) in normal responders, 5/20
(25%) in non-responders, and 14/56 (25%) in controls
(Table 2). The genotype frequency of the minor allele in
controls (25%) corresponds to an allele frequency of
13.4% for the G allele in controls.
Male patients with the major allele of OPRM1 had higher
concentrations of β-endorphin (26.8 ± 3.25 fmol/ml) than
male patients with the minor allele (24.2 ±2.96 fmol/ml;
p < 0.05). There were no differences in that respect among
female patients or in the control groups (Table 2). Fur-
thermore, a borderline significant association was found
in an age and sex adjusted model of OPRM1 and opioid
sensitivity (r = 0.188, adjusted R2 = 0.035 p = 0.106).ABCB1
ABCB1 allelic distribution was similar in all groups
(Figure 1). The frequency of the minor allele TT was 5/16
(31.75%) in high responders, 12/44 (27.2%) in normal
responders, 5/20 (25%) in non-responders, and 19/56 (34%)
in controls (Table 2).
There was a trend for different results among male
and female patients regarding β-endorphin levels. Men
with the minor allele TT tended to have higher
β-endorphin levels (27.4 ± 3.40 fmol/L) than men with
the major allele CC (25.8 ± 3.20 fmol/L). Similarly,
women with the major allele CC tended to have higher
β-endorphin levels (26.4 ± 3.30 fmol/L) than women
with the minor TT allele (24.9 ± 3.66 fmol/L; Figure 2).
Among patients with the minor TT allele, there was a
trend for sex differences in β-endorphin levels. Men
tended to have higher levels than women (p = 0.057;
Figure 2).
Patients with the minor TT allele also had more symp-
toms and side effects related to opioid treatment, such
as sweating, sedation, tension and stress, than other
patients (p < 0.05; Figure 3). The general quality of life
and emotional function results were also poorer in the
patients with the minor allele than in those with the
CT/CC alleles. No difference in the rating of pain was
noted between these groups, however (Figure 4).ormal responder Non responder Control
N=44 N=20 N=56
22% N=8 25% N=5 25% N=14
27% N=12 25% N=5 34% N=19
27% N=12 30% N=6 25% N=14
ormal, non-responders and in control subjects. Due to the low frequency of
s. For further details see Methods and Results.
Table 2 Plasma levels of β-endorphin
N β-endorphin fmol/L p
pain patients 80 26.2(3.59) <0.05
controls 56 28.2(4.63)
responder 60 26.6(3.57) <0.01
non-responder 20 24.7(3.20)
Pain patients
male OPRM1 AA 31 26.8(3.25) <0.05
male OPRM1 AG 8 24.2(2.96)
female OPRM1 AA 28 26.1(4.02) ns
female OPRM1 AG 11 25.9(3.50)
Controls
male OPRM1 AA 19 25.8(2.17) ns
male OPRM1 AG 6 31.5(9.13) ns
female OPRM1 AA 23 29.3(4.60) ns
female OPRM1 AG 8 28.2(1.63) ns
Plasma levels of the opioid peptide β-endorphin in patients with different
opioid sensitivity. For further details see Methods and Results.
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The CACNA2D2 allelic distributions are presented in
Figure 5. The minor CACNA2D2 G>A allele was not
found in any of the 16 high responders (0%), while 12/44
(27%) of the normal responder group, 6/20 (30%) of the
non-responders, and 15/56 (25%) of the control group
had this allele (Table 1). Thus, high responders to remifen-
tanil had a higher incidence of the major CACNA2D2
allele than normal responders, non-responders or controls
(p < 0.05). There was also a trend for men with the major
CACNA2D2 allele to respond better to opioids than men
with the minor allele (p = 0.087). In a multivariate model
adjusted for age and sex there was a significant association
between CACNA2D2 genotype and opioid sensitivity
(r = 0.247, adjusted R2= 0.067, p = 0.029).Figure 1 Genotype frequency of ABCB1. The genotype frequency of the
further details see Methods and Results.Discussion
The use of opioids for the treatment of chronic pain has
increased dramatically over the past decade [32,33]. How-
ever, as indicated above, the responsiveness to opioids in
chronic pain patients may vary depending on individual
differences but also on the type of pain [34,35]. For
instance, a number of studies have evidenced that neuro-
pathic pain patients are insensitive to opioids. The phar-
macodynamic response to a given opioid depends on the
nature of the receptor to which the opioid binds and its
affinity for the receptor. During recent years, a wide range
of candidate genes relevant to pain has been highlighted
[8] and these genes are associated with a variety of mole-
cules involved in pain processing, including neurotrans-
mitters and their receptors and transporters, metabolic
enzymes, ion channels, intracellular enzymes and second
messengers. Minor changes in allelic variability, like SNPs,
may affect the functionality of the encoded protein, result-
ing in an alteration of the protein activity or in the tran-
scription rate leading to lower or higher amounts of the
relevant protein [36]. An example of this is the decreased
μ-opioid receptor mRNA and protein expression in
human brain tissue in the presence of the OPRM1 118 G
variant [37].
This study focused on the genes for the μ-opioid pep-
tide (MOP) receptor, which mediates opioid effects, the
ABCB1 transporter of opioids, and the calcium channel
gene fragment α2δ, which affects the G-protein of the
opioid receptor. The effects of these gene variants were
in the present study measured in a group of patients
with chronic pain and the effects were correlated with
the perception of pain, the incidence of opioid side
effects, plasma levels of β-endorphin and opioid
sensitivity.
An important finding in the present study is that the
plasma levels of β-endorphin the endogenous ligand forABCB1 SNP in chronic pain with different opioid sensitivity. For
Figure 2 β-endorphin levels and the ABCB1 SNP. Plasma levels
of the opioid peptide β-endorphin in males and females with
different alleles of the ABCB1 SNP. A tendency towards sex
difference (p = 0.057) in the group carrying the minor TT allele is
indicated. For further details see Methods and Results. Values are
presented as mean ± SEM.
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chronic pain patients compared to control subjects. This
observation agrees with previous reported findings
showing that plasma levels of β-endorphin correlate
inversely with pain levels in patients with various pain
syndromes [38-42], i.e. the plasma concentration of this
opioid peptide are lower in patients with poorly con-
trolled pain but increase with pain relief [42]. Interest-
ingly, in the present study opioid responders had higherFigure 3 Scores of pain and other symptoms. Scores of pain and other
details see Methods and Results.plasma concentration of β-endorphin than non-
responders.
Our results also demonstrate that high responders to
remifentanil tended to be more likely to have the minor
allele of OPRM1 than normal responders, non-
responders or controls. However, there were too few
patients to confirm any statistical significance in this re-
gard. The study reported by Landau et al. [15] indicating
that women in labor who were homozygous for the
minor OPMR1 allele required less intrathecal fentanyl
than those with the major allele is in accordance with
our results. Similarly, Janicki and co-workers [43]
demonstrated that patients with chronic pain who were
homozygous for the minor allele used opioids less than
those carrying the major allele. Furthermore, men with a
higher pain threshold to experimental pressure pain
were more likely to have the minor allele of A118G [18].
Similarly, according to a report by Huang et al. [44]
women with the minor allele of the OPRM1 receptor
gene SNP IVS2+31 G>A have a higher pressure pain
threshold than women with the major allele. Taken
together, all these findings indicate that the minor alleles
of the OPRM1 gene could offer some protection from
pain and subsequently have decreased requirement for
opioids in chronic pain conditions.
In contrast, recent studies have indicated that patients
with malignant disease who have the minor allele of
OPRM1 require more morphine than those with the
major allele, and that patients who are undergoing
abdominal hysterectomy [45] or total knee arthroplasty
[46] who have the minor allele require larger intravenous
doses of morphine postoperatively than those with the
major allele. Also, a previous study has shown thatsymptoms for patients carrying the various ABCB1 alleles. For further
Figure 4 Quality of Life and symptom scores. Quality of Life (QoL) and symptom scores in patients carrying the various alleles of the ABCB1
gene. For further details see Methods and Results.
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of the OPRM1 A118G SNP than those with the A allele,
and subjects with the G allele were fount to require
more fentanyl for adequate postoperative pain control
than those with the A allele [47]. Other studies suggest
decreased sensitivity to the analgesic effects of opioids in
persons with the minor allele and protection from opioid
toxicity and side effects [48,49]. Thus, in patients with
acute postoperative and cancer pain, those with the
minor allele of OPRM1 require more morphine than
those with the major allele. However, the results of our
study suggest that the situation could be different in
patients with a phenotype of chronic pain from that in
patients with postoperative or cancer pain and healthy
subjects.
The consequence of the mutation A>G in the OPMR1
gene is an additional net charge with loss of a putative
glucosylation site in the area of the ligand-receptorFigure 5 The genotype frequency of CACNA2D2. The genotype freque
opioid sensitivity. For further details see Methods and Results.interaction and this feature may have consequences for
the sensitivity to opioids of pain patients, although the
phenotype of the pain seems to be essential.
Interestingly, the OPRM1 A118G SNP has also been
associated with higher heroin doses in addicted indivi-
duals [50]. In one of the first studies of the properties of
the A118G allele, Bond et al. found a threefold increase
in binding of β-endorphin [10], which could indicate
that people with the minor allele might be at risk of opi-
oid addiction. However, this finding has been disputed
by Beyer and co-workers [51]. The men with chronic
pain in our study who had the minor allele had lower
β-endorphin levels than the men with the major allele,
which could imply increased binding in the group with
the minor allele.
It should be noted that in the present study we present
data from the gene analysis as expressed in genotype
frequency (see Tables 1, 2, 3) in contrast to many otherncy of the CACNA2D2 gene in chronic pain patients with different






Sex M/F 39/41 25/31
Mean age (range) 46.2 (25-66) 40.5 (27-61)
Background data of the patients and controls participating in the study.
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frequency. This may give the impression that we report
a much higher frequency of the OPRM1 A118G allele in
our study population compared many other studies on
the Caucasian population. However, calculation of the
allele frequency in our material yields values that are in
good agreement with those reported from other labora-
tories [46].
Our study also suggests that there may be differences
between male and female patients regarding the effects
of genetic variation in the ABCB1 gene. Men with the
minor TT allele had higher β-endorphin levels than men
with the major CC allele but the reverse was true for
women. Sia and co-workers [52] demonstrated a trend
towards a higher risk of postoperative pain in women
with the T-allele a difference underlying the potential
importance of sex difference. Moreover, variants of the
ABCB1 gene may explain some portion of the inter-
strain differences in opioid-induced hyperalgesia in mice
and perhaps other consequences of chronic opioid
administration [53].
Furthermore, patients homozygous for the minor TT
allele of the ABCB1 gene experienced more opioid-
related side effects such as sweating, muscular tension,
stress and sedation than patients with the major CC/CT
alleles. This is in agreement with other studies indicating
an increased risk of opioid-induced side effects [54],
such as early respiratory depression with fentanyl treat-
ment [55]. It has been proposed that this effect involves
impairment of P-glycoprotein transport, resulting in
higher brain concentrations of the substrate (e.g. remi-
fentanil). However, earlier studies have indicated
decreased effects of methadone in patients with the
minor TT allele [13,56] and a smaller increase in R-
methadone levels with quetiapine [57]. The consequence
of this mutation in the ABCB1 gene may be related to
the effectiveness of the transporter P-glycoprotein,
encoded by this gene. The transporter P-glycoprotein, is
thus known to act on a broad range of prescription
medicines, including opioids. The ABCB1_3435C>T
SNP has been associated with mRNA, protein and
serum levels, and with responses to a number of medical
drugs [58].An interesting observation made in this study is that
the minor CACNA2D2 G>A SNP was not found in any
of the 16 high responders to remifentanil. This gene
encodes a member of the alpha-2/delta subunit family,
a protein in the voltage-dependent calcium channel
complex. All the high responders to the opioid remi-
fentanil had the major allele of CACNA2D2, suggesting
an association between this allele and high opioid
sensitivity. Interestingly, genetic variations of the Na+,
K+, and Ca2+−channel genes have also been associated
with migraine and neuropathic pain [59]. Very few, if
any, study on opioid sensitivity in relation to the gene
encoding the calcium channel fragment, CACNA2D2
allele, has so far been reported. Interestingly, a recent
study demonstrated an association between the
voltage-gated calcium channels and the A118G
OPRM1 polymorphism [60].
Thus, the effect of the mutation in the CACNA2D2
G>A allele will certainly affect the effectiveness of the
opioid. It is also essential for the action of β-endorphin in
pain processing pathways. The link between β-endorphin
and the calcium channel may be reflected by the observa-
tion that this opioid affects the inhibitory action of
OPMR1 on the calcium channel expressed on pathways
involved in nociception [60].
It is interesting to note that the low number of
patients examined in this study was sufficient to provide
some significant correlations in the group of patients
with chronic pain, a complex bio-psychosocial entity.
This was probably due to the homogeneity of the patient
groups, and the fact that this study focused on correlat-
ing the presence of the gene variation affecting the func-
tion of the μ-opioid receptor with its ligand β-endorphin
and opioid-related symptoms in a clinical population
with the same chronic pain syndrome. This study also
presents the gene for a calcium channel fragment as a
plausible contributor to individual variations in opioid
sensitivity. The sex variations were prominent, as has
been demonstrated in other studies. These results take
the issue of differences in opioid and pain sensitivity a
step further; sex and genetic variations could explain dif-
ferences in the pharmacokinetics and pharmacodynam-
ics of opioids.
Conclusions
This study confirms previously reported alterations in
the levels of circulating β-endorphin in chronic pain. It
further brings up the importance of genetic and sex
factors in sensitivity to opioids. Thus, in this study we
observed that the minor allele of the OPRM1 gene
tended to be associated with increased opioid sensitivity
in chronic pain, that there were sex differences in
β-endorphin levels and an increased incidence of opioid
side effects in patients with the minor allele of the
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ship between high opioid sensitivity and the presence of
the major allele of the CACNA2D2 gene.
Methods
Study population
Eighty patients with low back pain, who were scheduled
for lumbar fusion surgery and had been investigated for
opioid sensitivity, and 56 healthy volunteers were
recruited for the study. The patient group comprised 39
men and 41 women with a mean age of 46.2 (25–66)
years. The inclusion criteria were patients with chronic
low back pain for more than 6 months on the waiting
list for spinal fusion surgery. Age over 18 and ability to
understand written and spoken Swedish was required.
The patients were all scheduled for lumbar spinal fusion
surgery after having performed diagnostic MR indicating
degenerative disc disease, identification of diseased lum-
bar segment with discography and a clinical and neuro-
logical investigation by the orthopedic surgeon. At the
time for the remifentanil study the pain of the patient
was graded by visual analogue scale 0–100 mm. To be
included in this study the patients were required to
grade a minimum of 40 mm on this scale. The exclusion
criteria were significant comorbidity that would preclude
the planned operation. The control group consisted of
25 men and 31 women with a mean age of 40.5 (27–61)
years. The ethnicity of the patients and the control
population were mainly North European with the excep-
tion of 2 persons from each group that were of Middle
Eastern heritage. Blood samples from the patients and
healthy volunteers were collected and centrifuged. The
red blood cells and plasma were used for DNA-analyses
and for β-endorphin, respectively. Pain, QoL and opioid
side effects and symptoms were measured in both
patients and controls using the EORTC-OLQ-30 form.
The rationale for using this instrument was that it is
validated for opioid treated chronic pain and cancer
patients [61,62]. Opioid side effects such as obstipation,
nausea, sedation, sweating, dry mouth, pruritus, and
symptoms such as perceived stress and muscular tension
are evaluated in this instrument by the patients in the
terms of none (1) a little (2), moderate (3) or severe
disturbance (4). The numbers are then transcribed as
occurrence between 0-100% as described in the above
reference. The study was performed in compliance with
the Helsinki Declaration and the regional Ethical Review
Board in Uppsala approved the study. All patients and
controls signed a written informed consent.
All patients had received opioids, but none was receiv-
ing daily doses of strong opioids at the time of opioid
testing and blood sampling. The results obtained from
the patients were compared with those from the control
population of 56 healthy volunteers without pain.Test for opioid sensitivity with a target-controlled
infusion of Remifentanil
The patients were investigated for opioid sensitivity
using a target-controlled infusion of remifentanil, as
described by Schraag et al. [63]. This was a double-blind,
placebo-controlled investigation, where a significant
response was taken to be a 50% reduction in pain, using
a 100 mm visual analog scale, and a 50% increase in the
pressure pain threshold at the point of maximum pain
in the lower back. The pressure pain threshold was mea-
sured with an Algometer™ (Somedic AB, Sollentuna,
Sweden) as described by Kosek et al. [64]. Basically, the
instrument with a probe area of 1 cm2 and a rate of
pressure increase of 50 kPa/s was applied to the area of
maximal pain in the lumbar area and the patient indi-
cated the point when pressure was experienced as pain;
i.e. the pressure pain threshold. The target levels of
remifentanil that were measured for 50% pain relief were
1–7 ng/ml. High responders to remifentanil had blood
levels of the opioid in the range of 0.5–1.5 ng/ml, while
normal responders required 2–7 ng/ml. In non-responders
to remifentanil, the infusion had to be stopped because of
sedation or side effects before any pain relief was obtained.
There were 16 high responders, 44 normal responders and
20 non-responders.
DNA amplification
The Magtration 12GC system (Precision System Science,
Chiba, Japan) and the MagazorbW DNA Common Kit-
200 (PSS, Chiba, Japan) were used for the total genomic
DNA preparation from the whole blood samples. The
DNA-fragments containing the SNP site was amplified
in a reaction mixture on Mastercycler Ep Gradient S
(Eppendorf AG, Germany).
The first PCR for OPRM1 A118G were conducted
using the TaKaRa LA Taq (TaKaRam Shiga, Japan) at
95°C for 3 min, then 30 cycles of 95°C for 30 s, 60°C
for 30s and 72 for 1 min and hold at 4°C. PCR primers
were forward 5’-CTGACGCTCCTCTCTGTCTCA-3’
and reverse 5’CAACATTGAGCCTTGGGAGT-3’. The
second PCR were conducted with the identical pro-
gram but using the HotGoldStar DNA polymerase
(Eurogentec, Seraing, Belgium), using the primers for-
ward 5’GAAAAGTCTCGGTGCTCCTG 3’ and reverse
5’ GCACACGATGGAGTAGAGGG 3’.
PCR for CACNA2D2 was conducted with TaKaRa LA
Taq polymerase (TaKaRa, Shiga, Japan) by touch-down
PCR: 94°C for 3 min, then 10 cycles of 94°C for 20 s, 60°C
down to 50°C (−1°C/cycle) for 30s, 72°C for 1 min, then
25 cycles of 94°C for 20 s, 50°C for 30 s, 72°C for 1 min,
then 72°C for 10 min and hold at 4°C. Primers used were
forward 5’-AAGACGGATGGCCTCGTTA-3’ and reverse
5’-ACATATGGATGGCCAGTTGAA-3’. The second PCR
was conducted using the HotGoldStar DNA polymerase
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40 cycles of 94°C for 30 s, 65°C for 30 s, 72°C for 1 min and
ending with 72°C for 1 min and hold at 4°C, using primers
forward 5’-TCCAACATCACTCGGGCCAACT-3’ and re-
verse 5’-TTGTTGGCACAGGCCATCCACT-3’.
Amplification of ABCB1 was conducted with one PCR
at 94°C, 2 min, 94°C 30 sec, 60°C 30 sec, 68°C 1 min
30 cycles, 4°C hold using the AccuPrime Taq DNA poly-
merase (Invitrogen, Carlsbad, CA). Primers used were
forward 5’-GAGCCCATCCTGTTTGACTG-3’ and re-
verse 5’-ACTATAGGCCAGAGAGGCTGC-3´.
The PCR product was purified with the PCR Clean-Up
Kit (Invitrogen, Carlsbad, CA) using the Magtration
12GC system and the concentration were determined
using NanoDrop (Long beach, CA, USA).
SNP genotyping
The Handy Bio-Strand method was used for the SNP geno-
typing of OPRM1 A118G (rs1799971), as described earlier
[65]. Briefly, the amplified DNA was spotted on a micro-
porous nylon thread (Bio-Strand) and hybridized with
allele-specific oligonucleotide competitive hybridization
(ASOCH). The Cy5 oligonucleotide Cy5-Tag1 was used as
a landmark. The sequences of the positive controls, used to
confirm the SNP genotyping of OPRM1 A118G by
ASOCH, were as follows: 5’ GTCGGACAGGTTGCCATC
TAAGT 3’ (AA), 5’ GTCGGACAGGTCGCCATCTAAGT
3’ (GG). Hybridization was conducted automatically in
room temperature using the Magtration 12GC System.
The Bio-Strand Tip was first pre-hybridized by incubation
in 450 μl of a solution containing 2xSSC (1xSSC is
150 mM NaCl and 15 mM sodium citrate), 0.1% SDS and
200 μl/ml salmon sperm DNA (Invitrogen, Carlsbad, CA),
then incubated 5 min in 450 μl of the hybridization solu-
tion containing 2xSSC, 0.1% SDS, 200 μl/ml salmon
sperm DNA and 10nM Cy5 probes. The Bio-strand Tip
was washed for 2 min each in 450 μl washing buffer 1
(2xSSC and 0.1% SDS) washing buffer 2 (1xSSC and 0.1 %
SDS), washing buffer 3 (0.1xSSC and 0.1% SDS) and then
soaked in 450 μl of 2xSSC. The Cy5 probes for ASOCH
were: 5’-ATGGCGACCTG 3’ (G), 5’ Cy5-ATGGC
AACCTG 3’ (A). Two non-labeled oligonucleotides were
used as competitor to the Cy5-probes, (5’-ATGG
CAACCTG-3’) for G and (5’-ATGGCGACCTG-3’) for A.
The Cy5 fluorescent signal was scanned with the Handy
Bio-Strand scanner (PSS, Chiba, Japan) and the results
were analyzed with Hy-Soft software (PSS, Chiba, Japan).
In addition, all OPRM1 SNP were confirmed by PCR
direct sequencing.
PCR direct sequencing was used to analyse CACNA2D2
G>A (rs5030977) and ABCB1 C3435T (rs1045642) SNP
genotypes. Briefly, the PCR-product was mixed with
Exo-SAP-IT (USB, Cleveland, OH, USA), diluted 1:20
with H2O and incubated in 37°C, 30 min. Exo-SAP-ITwas inactivated by heating at 80°C for 20 min. Direct
DNA sequencing were performed at Macrogen (Seoul,
Korea).
Radioimmunoassay
The frozen plasma samples were thawed on ice and cen-
trifuged at 4°C for 10 min at 3000 × g. The supernatants
were collected, diluted (1:5) with 0.1 M formic acid and
0.018 M pyridine (buffer I) and separated on minicol-
umns (1 ml) packed with SP-Sephadex C-25 gel accord-
ing to a previously outlined procedure [66]. The
columns were washed with 10 ml buffer I and then, after
application of the sample, washed with additional 5 ml
of 0.1 M formic acid/0.1 M pyridine, pH 4.4 (buffer II).
The peptide-containing fractions were then eluted with
4 ml of 1.6 M formic acid/1.6 M pyridine, pH 4.4 (buffer
V). All buffers contained 0.01% mercaptoethanol. The
eluted samples were then evaporated in a Speed Vac
centrifuge (Savant, Hicksville, NY, USA).
The EURIA-β-Endorphin kit (EURO-DIAGNOSTICA
AB, Sweden) was used for the β-endorphin radio-
immunoassay (RIA). This RIA is based on the principle
of double-antibody precipitation. The evaporated sam-
ples were diluted with 220 μl diluent (0.05 M phosphate,
pH 7.4, 0.25% human serum albumin, 0.05% sodium
azide, 0.25% EDTA and 500 KIU TrasylolW/ml) and
incubated with 100 μl of anti-β-endorphin antiserum for
24 h at 4°C. After incubation, the labeled peptide was
added to each sample and incubated for an additional
24 h, at 4°C. Thereafter, the double antibody PEG was
added, and the test tubes were incubated for 60 min and
then centrifuged for 15 min at 3000 × g at 4°C. Finally,
the supernatants were decanted and the radioactivity of
the precipitates was counted in a gamma counter.
Statistical methods
The material was analyzed with SPSS 14 quantitative
data using Student’s t-tests. Ordinal data and variables
not normally distributed were analyzed by the Mann–
Whitney U-test, the Kruskal Wallis test and the z-test
for comparison of population proportions. Hardy-
Weinberg equilibrium was assessed for each SNP by
χ2 analyses. The findings in univariate analyses were
furthermore investigated in multivariate models adjusted
for age and sex.
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